Stronger CMV treatment for lung transplant recipients
Treatments studied
Part of Immune system & allergy, Infections, Lungs & breathing clinical trials.
This trial tests adding a drug called letermovir to standard antiviral therapy for lung transplant patients with CMV infection. The goal is to see if the combination helps clear the virus faster and more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a lung transplant.
- You have an active CMV infection with a viral load of at least 1000 IU/mL.
- You are about to start or have just started (within the last 72 hours) standard antiviral treatment for CMV.
- You do not have severe kidney failure (creatinine clearance below 15 mL/min or on dialysis).
- You do not have severe liver disease (Child-Pugh Class C).
- You are not taking cyclosporin, pimozide, or ergot alkaloids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two antiviral medications to prevent CMV (a common virus that can cause problems after kidney transplant) in people who had the virus before their transplant. The goal is to see which medicine works better and is safer for preventing CMV disease.
This trial tests whether taking letermovir for a longer time can prevent CMV (a common virus) from reactivating in adults with certain risk factors after a donor stem cell transplant. If you're preparing for your first transplant and have a high-risk donor or conditioning, this study may be an option.
This trial tests whether the drug letermovir can prevent cytomegalovirus (CMV) infection in people who have had a stem cell transplant. It is for adults who are CMV-positive and have not yet had a CMV infection.
This study compares a new antiviral drug (letermovir) to a standard one (valganciclovir) for preventing CMV infection after lung transplant. It is for people who are at high risk because the donor had CMV but the recipient did not.
This trial tests if an oral medication called letermovir can prevent CMV infection in heart or lung transplant recipients who are at risk for CMV. It may offer a convenient option to protect against this virus after transplant.
This trial tests a combination of two antiviral drugs (letermovir and valganciclovir) to treat CMV infections in kidney transplant recipients. It aims to find a safer, more effective treatment option for people with active CMV after transplant.
Hear when a new CMV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.